Skip to main content

What is the success rate of Breyanzi?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on March 31, 2025.

Official Answer by Drugs.com

The success rate of Breyanzi (lisocabtagene maraleucel) varies depending on the condition being treated. Clinical trial data show that complete response rates range from 20% to 73% across different types of lymphoma and leukemia.

Below are clinical trial results for Breyanzi in various conditions, with some patients experiencing partial response to treatment.

Large B-cell lymphoma

Breyanzi was studied in over 250 adults with refractory or relapsed B-cell lymphoma in a multicenter clinical trial. The study showed:

Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

The complete response rate among patients who took Breyanzi for relapsed or refractory CLL or SLL in a clinical trial called TRANSCEND-CLL was 20%. A total of 65 patients were treated with Breyanzi in the study.

Related questions

Follicular lymphoma

In the TRANSCEND-FL clinical trial, adults with relapsed or refractory follicular lymphoma who took Breyanzi had a complete response rate of 73.4%. A total of 94 patients that were treated with Breyanzi were included in the final results. In order to be considered to have complete response, patients who did not have a negative bone marrow biopsy between their most recent disease progression and before starting lymphodepleting chemotherapy were required to have a negative bone marrow biopsy.

Mantle cell lymphoma

Out of 68 patients with relapsed or refractory mantle cell lymphoma who were treated with Breyanzi in the TRANSCEND-MCL trial, 67.6% saw a complete response.

Individual responses to Breyanzi vary, and partial responses were also observed in these trials. Speak with your healthcare provider to understand how these results may apply to your specific situation.

References

Breyanzi [package insert]. Updated May 2024. Juno Therapeutics, Inc. Accessed August 6, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed

U.S. Food and Drug Administration. 2021. FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma. Accessed August 6, 2024 at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-or-refractory-large-b-cell-lymphoma

U.S. Food and Drug Administration. 2024. FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma

U.S. Food and Drug Administration. 2024. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma

Read next

What is the cost of Kymriah?

Kymriah (tisagenlecleucel) is an expensive CAR-T cell cancer therapy costs over $612,000 for one treatment infusion, but most people do not pay this amount. In addition, the Centers for Medicare & Medicaid Services (CMS) states that CAR-T cell therapy would be covered for eligible people with Medicare. Continue reading

What's the difference between Kymriah and Yescarta?

Kymriah and Yescarta are two cell-based gene therapies. A few differences between the two medications include who and what they are FDA approved for, their dosage, and which companies make them. Continue reading

How does Monjuvi work?

Monjuvi (tafasitamab-cxix injection) is a targeted immunotherapy drug and works by helping the immune system find and kill cancer cells in people living with advanced diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).

Continue reading

See also:

Related medical questions

Drug information

Related support groups